US EditionPublished • loading... • Updated
Is the future of Big Pharma already in China?
Summary by Vogon Today
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Is the future of Big Pharma already in China?
From Merck to AstraZeneca, passing through Bristol Myers Squibb, GSK, and Eli Lilly. While the United States is reducing public funding and risks losing its leadership in the sector, Western Big Pharma has already invested over $150 billion between 2020 and 2025 in agreements with Asian companies, 65% of which in China. Facts and figures Recent years have seen a profound transformation in the global biopharmaceutical industry. A growing wave of …
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
